WO2012018145A3 - Agent pour améliorer la qualité de vie - Google Patents

Agent pour améliorer la qualité de vie Download PDF

Info

Publication number
WO2012018145A3
WO2012018145A3 PCT/JP2011/068339 JP2011068339W WO2012018145A3 WO 2012018145 A3 WO2012018145 A3 WO 2012018145A3 JP 2011068339 W JP2011068339 W JP 2011068339W WO 2012018145 A3 WO2012018145 A3 WO 2012018145A3
Authority
WO
WIPO (PCT)
Prior art keywords
life
agent
improving
quality
hepatocellular carcinoma
Prior art date
Application number
PCT/JP2011/068339
Other languages
English (en)
Japanese (ja)
Other versions
WO2012018145A2 (fr
Inventor
光彦 川口
義人 畝
研介 後藤
太乙 郭
喜治 角田
栄一 平野
Original Assignee
株式会社日本生物製剤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社日本生物製剤 filed Critical 株式会社日本生物製剤
Publication of WO2012018145A2 publication Critical patent/WO2012018145A2/fr
Publication of WO2012018145A3 publication Critical patent/WO2012018145A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne un agent pour améliorer la qualité de vie de patients atteints d'un carcinome hépatocellulaire. Cet agent est caractérisé en ce qu'il contient un extrait de placenta humain, et qu'il est de préférence utilisé simultanément avec un agent d'amélioration de la fonction hépatique (par exemple, un glycyrrhizinate). Cet agent permet de faire rétrécir les cellules d'hépatome, de soulager les symptômes subjectifs des patients et d'améliorer leur qualité de vie, et ainsi, cet agent est particulièrement efficace pour traiter un carcinome hépatocellulaire, y compris un carcinome hépatocellulaire au stade terminal.
PCT/JP2011/068339 2010-08-05 2011-08-04 Agent pour améliorer la qualité de vie WO2012018145A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010176441 2010-08-05
JP2010-176441 2010-08-05

Publications (2)

Publication Number Publication Date
WO2012018145A2 WO2012018145A2 (fr) 2012-02-09
WO2012018145A3 true WO2012018145A3 (fr) 2012-03-29

Family

ID=45559888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/068339 WO2012018145A2 (fr) 2010-08-05 2011-08-04 Agent pour améliorer la qualité de vie

Country Status (1)

Country Link
WO (1) WO2012018145A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526469A (ja) * 2012-08-20 2015-09-10 ボリス, マルコシアンMarkosian, Boris 癌に対する胎盤ワクチン接種療法
JP2022140106A (ja) * 2021-03-12 2022-09-26 国立大学法人九州大学 プラセンタ抽出物の使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058243A1 (fr) * 2002-12-26 2004-07-15 Ajinomoto Co., Inc. Inhibiteur de l'apparition et de l'evolution du cancer du foie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058243A1 (fr) * 2002-12-26 2004-07-15 Ajinomoto Co., Inc. Inhibiteur de l'apparition et de l'evolution du cancer du foie

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HIDEMORI SAKAMOTO ET AL.: "Placenta Chiryo ga Soko shita to Omowareru Tahatsusei Kan Saibo Gan no Ichi Rei", DAI 94 KAI JAPANESE SOCIETY OF GASTROENTEROLOGY KYUSHU SHIBU REIKAI/DAI 88 KAI JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY KYUSHU SHIBU REIKAI PROGRAM - SHOROKUSHU, 2009, pages 132 *
MAHIKO NAGASE: "Placental therapy", EASTERN MEDICINE, vol. 20, no. 3, 25 February 2005 (2005-02-25), pages 31 - 38 *
NOBUHIRO KAWANO ET AL.: "Remarkable regression of hepatocellular carcinoma by reduced glutathion: A case report", ACTA HEPATOLOGICA JAPONICA, vol. 25, no. 11, 25 November 1984 (1984-11-25), pages 1468 - 1473 *
TATSURO TAKINO ET AL.: "Clinical effects of hepatotherapeutic drugs on chronic liver diseases", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 136, no. 13, 29 March 1986 (1986-03-29), pages 1177 - 1181 *
YASUSHI TSUZUKI: "Taiban Seizai (Melsmon) no Gan Kanja eno Koka ni Tsuite", CLINICAL REPORT, vol. 12, no. 12, November 1978 (1978-11-01), pages 3325 - 3326 *
YUKIO GIBO: "B Gata, C Gata Mansei Kan'en, Kankohen ni Taisuru Kan Higoyaku no Tsukaikata", MEDICINA, vol. 41, no. 10, 10 October 2004 (2004-10-10), pages 1648 - 1650 *

Also Published As

Publication number Publication date
WO2012018145A2 (fr) 2012-02-09

Similar Documents

Publication Publication Date Title
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
WO2009152084A3 (fr) Cellules souches dérivées d'un tissu adipeux à usage vétérinaire
WO2012048099A3 (fr) Cellules chargées de nanoparticules
WO2011061330A3 (fr) Utilisation d'agents rafraîchissants physiologiques et produits contenant de tels agents
WO2008063842A3 (fr) Méthodes de traitement de la douleur neuroapathique au moyen d'agonistes de ppar-gamma
WO2012012682A3 (fr) Méthodes destinées à traiter ou à améliorer des maladies et à renforcer la performance comprenant l'utilisation d'une solution stabilisée par un dipôle magnétique
WO2013186240A3 (fr) Analogue peptidique d'exendine-4
WO2012129084A3 (fr) Inhibiteurs de la glucosylcéramide synthase
WO2010135692A3 (fr) Biomarqueurs miarn d'une maladie prostatique
WO2010102195A3 (fr) Gène de l'annexine a11 et gènes associés en tant que biomarqueurs pour le cancer
IN2014MN02089A (fr)
WO2012074930A3 (fr) Composition à faible éructation et méthodes de traitement et/ou de prévention de maladie cardiovasculaire chez un sujet présentant une allergie/hypersensibilité aux poissons
WO2010062863A3 (fr) Compositions contenant des satiogènes et leurs procédés d'utilisation
WO2011083464A3 (fr) Procédés pour l'utilisation d'un agent adénoviral antiangiogenèse spécifique
WO2014031859A3 (fr) Compositions et méthodes se rapportant à des biomarqueurs sanguins du cancer du sein
MX2013011833A (es) Formula infantil para ser usada en la prevencion de enfermedades cardiovasculares.
WO2012142413A3 (fr) Compositions à base de nitrite et leurs utilisations
WO2013117744A3 (fr) Méthodes de traitement de la fibrose
WO2011163566A3 (fr) Méthodes de traitement de patients souffrant de maladies se rapportant au système immunitaire
WO2010086838A3 (fr) Vecteurs adénoviraux non ad5 et procédés et utilisations associés
WO2012053823A3 (fr) Protéine hybride présentant une activité du facteur ix
WO2014195847A3 (fr) Nouvelle utilisation du l-tryptophane marqué par un isotope stable
WO2012018145A3 (fr) Agent pour améliorer la qualité de vie
WO2009098355A8 (fr) Nouvelle utilisation de probiotiques
WO2009059239A3 (fr) Réduction des niveaux d'aβ42 et de l'agrégation d'aβ

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11814766

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11814766

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: JP